Big pharma, Partnering

Abbvie and C2N partner for anti-tau antibodies for Alzheimer’s Disease

Posted on 20 March 2015

Tags: , ,

AbbVie has entered into an exclusive worldwide license agreement with C2N Diagnostics to develop and commercialize a portfolio of anti-tau antibodies for the treatment of Alzheimer's Disease and other neurological disorders.

This partnership builds upon AbbVie's commitment to pursue transformational disease-modifying therapies in Alzheimer's Disease.

Tau stabilizes proteins that are responsible for the structure and transport in neuronal cells.

Searching for more deal information? Current Partnering offers the following options:

  • CP Reports | Browse titles | Over 200 report titles that focus upon different deal types from licensing, co-promotion to distribution, biomarkers to drug delivery, oncology to psychiatry, all of which provide you with an insight into the latest life science deal making trends
  • Current Agreements | Login | Find out more | Updated daily by our industry analysts, our fully searchable life sciences intelligence database allows you to find deals and alliances dating as far back as 2000 saving you valuable time on your deal making research activities
  • CP Knowledge Centre | Login | Find out more | Provides you with an all-in-one intelligence package that allows you to simultaneously access our CP reports, CP Insight and Current Agreements deal and alliances database, at the same time

 

Abnormal accumulation of altered tau protein is a leading indicator in a variety of neurodegenerative conditions including Alzheimer's Disease, Progressive Supranuclear Palsy and Corticobasal Degeneration.

In these conditions, the development of tau pathology strongly correlates with clinical disease progression.

Financial terms of the collaboration were not disclosed.

For further deal information visit Current Agreements (subscription required)

Related

Scorecard: Top partnering deals by value in 2015

View: Top pharmaceutical companies

View: Top biotech companies

Reports: Browse our extensive deal making report portfolio

Print Friendly, PDF & Email

Leave a Reply